Related Experiment Video
Updated: May 11, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Upstream therapy for atrial fibrillation].
1Fukuoka Sanno Hospital, Heart Rhythm Center.
Summary
Upstream therapies like ACE inhibitors and ARBs may prevent new atrial fibrillation (AF) in heart disease patients. Evidence for statins in AF prevention is limited, except post-surgery.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Atrial remodeling, often linked to hypertension, heart failure, and inflammation, can lead to atrial fibrillation (AF).
- Upstream therapies aim to prevent or mitigate this remodeling to reduce AF incidence and progression.
Purpose:
- To evaluate the efficacy of upstream therapies, specifically angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), and statins, in preventing new-onset, recurrent, or progressive atrial fibrillation.
- To assess the strength of evidence supporting these treatments in various patient populations with underlying heart conditions.
Summary:
- ACEI and ARB treatments show sustained reduction in new-onset AF for patients with significant heart disease, though evidence is less robust for moderate conditions or recurrent AF.
- Current evidence for statins in preventing AF, excluding post-operative cases, is insufficient for strong recommendations.
- Consensus on optimal statin therapy (intensity, duration, type) for AF prevention is lacking.
Impact:
- Findings highlight the potential role of ACEI and ARB as preventative strategies for atrial fibrillation in specific patient groups.
- Identifies gaps in evidence regarding statin efficacy for AF prevention, guiding future research.
- Informs clinical practice by differentiating the established benefits of ACEI/ARB from the uncertain role of statins in AF management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...